Publication | Closed Access

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Disease ManagementProof-of-concept TrialSymptomatic TreatmentCovid-19 PandemicClinical TrialsHospitalised PatientsCovid-19 EpidemiologyPhase 2MedicineCovid-19